Christopher Griffiths, Dermatology Meeting News 2021: Guselkumab VOYAGE-1 Study

It was an absolute pleasure to speak with Prof. Christopher Griffiths (University of Manchester, Manchester, UK) about recent developments in the treatment of psoriasis including the VOYAGE study. 

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  

Questions

1. Could you tell us about the aims and design of the VOYAGE 1 study? (00:10-01:14)
2. What has the study taught us about the efficacy and safety of guselkumab in psoriasis? (01:14-02:25)
3. There are other novel IL-17/23 antagonists currently in development e.g. bimekizumab and mirikizumab, based on clinical data to date, which are you most excited/optimistic about? (02:25-03:42)

Disclosures: Christopher Griffiths has the following disclosures: AbbVie  – (AD Board, Grant Holder), Almirall (Advisor), Amgen (Advisor), BMS (Speaker, Grant Holder) , Boehringer Ingelheim (Ad Board / Advisor), Celgene  – (Ad Board / Speaker) , Galderma – (AD Board, Grant Holder) , Janssen – (Speaker, Grant holder) , LEO Pharma (Grant Holder / Speaker) , Lilly – (Grant Holder / Ad Board) , MSD (Advisor), Novartis (Ad Board / Speaker / Ad Board), Pfizer – (Grant Holder, Speaker) , Sandoz  (Grant Holder) and UCB Pharma – (AD Board)

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.